Epithalon vs NAD+: Anti-Aging Peptide Research Compared

# Epithalon vs NAD+: Anti-Aging Peptide Research Compared

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

Epithalon and NAD+ (or its precursors NMN and NR) represent two distinct approaches to anti-aging research, each targeting different fundamental mechanisms of cellular aging. Epithalon focuses on telomere biology; NAD+ focuses on mitochondrial function and sirtuin activation. Understanding the differences in their mechanisms and evidence bases is important for researchers designing anti-aging studies.

Mechanism Comparison

Epithalon — Telomerase Activation: - Proposed to activate telomerase (hTERT), the enzyme that extends telomeres - Targets telomere attrition — one of the primary hallmarks of aging - Also studied for effects on pineal gland function and melatonin production - Mechanism is specific to the telomere/telomerase biology

NAD+ — Metabolic and Epigenetic Regulation: - Serves as a coenzyme in oxidative phosphorylation (mitochondrial energy production) - Activates sirtuins (SIRT1-7), which regulate metabolism, DNA repair, and stress resistance - Supports PARP enzymes for DNA damage repair - Targets multiple hallmarks of aging: mitochondrial dysfunction, nutrient sensing deregulation, genomic instability

Evidence Base Comparison

Epithalon: The Epithalon evidence base is dominated by research from Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. While this research is published in peer-reviewed journals, the concentration of evidence from a single research group limits independent validation.

Key findings: - Telomerase activation in human fibroblasts (Khavinson et al., 2003) - Lifespan extension in rodent models (up to 16% in some studies) - Improved immune function markers in elderly subjects in small clinical studies

NAD+: The NAD+ evidence base is substantially more distributed across research groups and includes multiple human clinical trials. Key findings include: - NMN supplementation restores NAD+ levels in aging mice and improves multiple aging parameters (Yoshino et al., 2011) - NR supplementation increases NAD+ levels in humans (Trammell et al., 2016) - Human trials with NMN demonstrate improved muscle insulin sensitivity in postmenopausal women (Yoshino et al., 2021) - Sirtuin activation by NAD+ has been demonstrated in multiple independent research groups

The NAD+ evidence base is considerably stronger in terms of independent replication and human clinical data.

Practical Research Considerations

Epithalon: - Administered by subcutaneous or intravenous injection - Typical research protocols use 5-20 day courses - Lyophilized peptide requires reconstitution - Limited human clinical trial data

NAD+ precursors (NMN, NR): - Can be administered orally (significant advantage for research protocols) - Well-tolerated in human studies with minimal adverse effects - Multiple suppliers with varying quality — purity verification important - Extensive human clinical trial data available

Complementarity

Epithalon and NAD+ target largely non-overlapping mechanisms of aging, which provides a rationale for studying them together rather than choosing between them. Epithalon addresses telomere attrition; NAD+ addresses mitochondrial dysfunction and nutrient sensing. The combination has not been studied in a single model, but the mechanistic complementarity is clear.

References

1. Khavinson, V.K., et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592.
2. Yoshino, J., et al. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 14(4), 528–536.
3. Trammell, S.A., et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nature Communications, 7, 12948.